D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 84 Citations 57,691 301 World Ranking 9779 National Ranking 5174

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Cancer

His scientific interests lie mostly in Internal medicine, Gastroenterology, Ribavirin, Hepatitis C and Surgery. His study in Internal medicine is interdisciplinary in nature, drawing from both Alpha interferon, Immunology and Hepatitis C virus. His biological study spans a wide range of topics, including Liver biopsy, Viral hepatitis, Virology, Peginterferon alfa-2b and Placebo.

His work in Ribavirin is not limited to one particular discipline; it also encompasses Viral load. His Surgery research is multidisciplinary, incorporating elements of Pediatrics and Transjugular intrahepatic portosystemic shunt. His Interleukin 28B research is multidisciplinary, relying on both Boceprevir and Telaprevir.

His most cited work include:

  • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. (5906 citations)
  • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. (5627 citations)
  • Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C (3274 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Internal medicine, Gastroenterology, Ribavirin, Cirrhosis and Hepatitis C. The Internal medicine study combines topics in areas such as Chronic hepatitis, Surgery, Immunology and Hepatitis C virus. His study in Gastroenterology is interdisciplinary in nature, drawing from both Fibrosis, Interferon, Placebo and Liver biopsy.

His Ribavirin study combines topics from a wide range of disciplines, such as Adverse effect and Alpha interferon. His Cirrhosis research incorporates themes from Hepatocellular carcinoma and Nonalcoholic fatty liver disease. His Hepatitis C research incorporates elements of Viral hepatitis, Pharmacotherapy, Randomized controlled trial and Hepatology.

He most often published in these fields:

  • Internal medicine (72.77%)
  • Gastroenterology (60.64%)
  • Ribavirin (33.41%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (72.77%)
  • Gastroenterology (60.64%)
  • Cirrhosis (25.86%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Gastroenterology, Cirrhosis, Placebo and Fibrosis. His studies in Internal medicine integrate themes in fields like Sofosbuvir/velpatasvir, Ribavirin and Hepatitis C virus. His Ribavirin research focuses on subjects like Alpha interferon, which are linked to Peginterferon alfa-2a and Viral load.

His work deals with themes such as Adverse effect, Randomized controlled trial and Obeticholic acid, which intersect with Gastroenterology. His work investigates the relationship between Cirrhosis and topics such as Hepatocellular carcinoma that intersect with problems in Pediatrics and Liver transplantation. His studies deal with areas such as Nonalcoholic fatty liver disease, Biopsy, Liver biopsy and Steatosis as well as Fibrosis.

Between 2015 and 2021, his most popular works were:

  • Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response (146 citations)
  • Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis (105 citations)
  • The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. (72 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Surgery
  • Cancer

His scientific interests lie mostly in Internal medicine, Gastroenterology, Cirrhosis, Placebo and Fibrosis. His study looks at the relationship between Internal medicine and topics such as Hepatitis C virus, which overlap with Regimen. Mitchell L. Shiffman has researched Gastroenterology in several fields, including Surgery, Liver biopsy, Adverse effect and Nonalcoholic fatty liver disease, Fatty liver.

His biological study spans a wide range of topics, including Liver disease, Steatohepatitis and Hazard ratio, Confidence interval. His research integrates issues of Ursodeoxycholic acid, Tolerability, Clinical endpoint, Randomized controlled trial and Primary sclerosing cholangitis in his study of Placebo. Immunology covers Mitchell L. Shiffman research in Ribavirin.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Michael W. Fried;Mitchell L. Shiffman;K. Rajender Reddy;Coleman Smith.
The New England Journal of Medicine (2002)

8456 Citations

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Michael P. Manns;John G. McHutchison;Stuart C. Gordon;Vinod K. Rustgi.
The Lancet (2001)

8286 Citations

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

John G. Mchutchison;Stuart C. Gordon;Eugene R. Schiff;Mitchell L. Shiffman.
The New England Journal of Medicine (1998)

4493 Citations

Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities

Arun J. Sanyal;Carol Campbell-Sargent;Faridoddin Mirshahi;William B. Rizzo.
Gastroenterology (2001)

2584 Citations

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Patrick Marcellin;Ting Tsung Chang;Seng Gee Lim;Myron J. Tong.
The New England Journal of Medicine (2003)

2003 Citations

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir.
The New England Journal of Medicine (2009)

1767 Citations

Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

Gary L. Davis;Rafael Esteban-Mur;Vinod Rustgi;John Hoefs.
The New England Journal of Medicine (1998)

1584 Citations

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro.
The New England Journal of Medicine (2014)

1429 Citations

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B

Patrick Marcellin;E Jenny Heathcote;Maria Buti;Ed Gane.
The New England Journal of Medicine (2008)

1389 Citations

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

Pouneh Mofrad;Melissa J. Contos;Mahmadul Haque;Carol Sargeant.
Hepatology (2003)

1372 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Mitchell L. Shiffman

Stefan Zeuzem

Stefan Zeuzem

Goethe University Frankfurt

Publications: 262

Patrick Marcellin

Patrick Marcellin

Université Paris Cité

Publications: 205

Zobair M. Younossi

Zobair M. Younossi

Inova Health System

Publications: 189

Jean-Michel Pawlotsky

Jean-Michel Pawlotsky

Université Paris Cité

Publications: 161

Michael P. Manns

Michael P. Manns

Hannover Medical School

Publications: 155

Maria Buti

Maria Buti

Instituto de Salud Carlos III

Publications: 148

Kazuaki Chayama

Kazuaki Chayama

Hiroshima University

Publications: 144

Hiromitsu Kumada

Hiromitsu Kumada

Fukuoka University

Publications: 142

Ira M. Jacobson

Ira M. Jacobson

New York University

Publications: 140

Mark S. Sulkowski

Mark S. Sulkowski

Johns Hopkins University School of Medicine

Publications: 139

Arun J. Sanyal

Arun J. Sanyal

Virginia Commonwealth University

Publications: 131

Stanislas Pol

Stanislas Pol

Université Paris Cité

Publications: 126

Fabien Zoulim

Fabien Zoulim

Inserm

Publications: 125

Christoph Sarrazin

Christoph Sarrazin

Goethe University Frankfurt

Publications: 122

Heiner Wedemeyer

Heiner Wedemeyer

Hannover Medical School

Publications: 122

Robert S. Brown

Robert S. Brown

Cornell University

Publications: 120

Trending Scientists

Vassilis Christophides

Vassilis Christophides

École Nationale Supérieure de l'Électronique et de ses Applications

Liuchen Chang

Liuchen Chang

University of New Brunswick

Ahmad Pesaran

Ahmad Pesaran

National Renewable Energy Laboratory

Dietmar Stalke

Dietmar Stalke

University of Göttingen

Kazuki Sada

Kazuki Sada

Hokkaido University

James A. McCloskey

James A. McCloskey

University of Utah

Akihiko Hirata

Akihiko Hirata

Waseda University

Paul Eggleton

Paul Eggleton

Natural History Museum

Neal W. Menzies

Neal W. Menzies

University of Queensland

Angela Bachi

Angela Bachi

FIRC Institute of Molecular Oncology

Paul E. Love

Paul E. Love

National Institutes of Health

Tatsuru Masuda

Tatsuru Masuda

University of Tokyo

Margaret A. Fischl

Margaret A. Fischl

University of Miami

Martin J. Siegert

Martin J. Siegert

Imperial College London

Prabha Siddarth

Prabha Siddarth

University of California, Los Angeles

Doreen Massey

Doreen Massey

The Open University

Something went wrong. Please try again later.